Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | DHFR | P00374 | 4/20 | 0.34 |
| ▸ | NOS1 | P29475 | 3/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4361085 | 0.86 | HSD17B10 (0.48) | HSD17B10PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL25899104 | 0.83 | ADORA2A (0.48) | PIK3CGPIK3CAPIK3CBHDAC6ADORA2A | |
| SCHEMBL11628253 | 0.83 | PIK3CG (0.35) | HSD17B10PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL25899163 | 0.81 | HSD17B10 (0.34) | HSD17B10 | |
| SCHEMBL24629319 | 0.80 | PIK3CG (0.42) | PIK3CGPIK3CAPIK3CBHDAC6ADORA2A | |
| SCHEMBL9201051 | 0.80 | HSD17B10 (0.38) | HSD17B10PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL25899167 | 0.78 | HSD17B10 (0.32) | HSD17B10 | |
| SCHEMBL6239850 | 0.77 | PIK3CG (0.41) | PIK3CGPIK3CAPIK3CBHDAC6ADORA2A | |
| SCHEMBL11301495 | 0.77 | HSD17B10 (0.38) | HSD17B10PIK3CGPIK3CAPIK3CBHDAC6 | |
| Xanthopterin SCHEMBL906220 | 0.77 | PIK3CG (0.46) | PIK3CGPIK3CAPIK3CBHDAC6ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | HSD17B10 4659/4885PIK3CG 1942/4885PIK3CA 2942/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | HSD17B10 4755/4885PIK3CG 1698/4885PIK3CA 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.